

from the group consisting of maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acid in the form of a racemate or an isomer.

24. (Amended) A pharmaceutical dosage form which comprises a coated tablet having a sustained-release core, said core comprising a combination of:

- a) mizolastine as active principle;
- b) a fatty matrix; and
- c) an organic acid;

and wherein the mizolastine comprises from 0.5% to 12% by weight of the dosage form.

25. (Amended) A sustained-release pharmaceutical dosage form according to claim 24 wherein the weight ratio of the mizolastine to the organic acid is between 0.3 and 1.

---

31. (Amended) A coated sustained-release tablet having:

- a) a core comprising mizolastine, a fatty matrix and an organic acid;
  - b) a dissolution profile which is pH independent; and
  - c) wherein the mizolastine comprises from 0.5% to 12% by weight of the tablet.
-